AstraZeneca admits Covishield may lead to rare side effects

AstraZeneca has made a significant admission in court documents, acknowledging for the first time that its Covid-19 vaccine can lead to rare side effects, including Thrombosis with Thrombocytopenia Syndrome (TTS), characterized by blood clots and low blood platelet counts.

In India and other low- and middle-income countries, the Covid-19 vaccine developed by AstraZeneca in collaboration with the University of Oxford was manufactured and distributed under the brand name “Covishield” by the Serum Institute of India (SII).

This arrangement was made possible through a licensing agreement between SII, the University of Oxford, and AstraZeneca, allowing for the production and distribution of the vaccine to a broader population, particularly in countries where access to vaccines and healthcare resources may be limited.

This admission comes amidst a class action lawsuit alleging serious injury and death caused by the vaccine, with claims that its efficacy was overstated and that it is defective.

Also Read: Experts warn about outbreak of bird flu, say could be 100 times worse than Covid-19

The legal proceedings involve 51 cases filed in the court, with plaintiffs and their families seeking damages totaling up to £100 million. The first case, initiated in 2023 by Jamie Scott, involves permanent brain injury allegedly linked to the vaccine received in April 2021.

AstraZeneca initially disputed the connection between TTS and its vaccine but later admitted the potential rare side effect in court documents.

Kate Scott, wife of Jamie Scott, expressed hope for progress following AstraZeneca’s admission, emphasizing the need for accountability, compensation, and timely resolution for affected families.

She highlighted the significance of AstraZeneca’s acknowledgment after years of questioning and denial, stressing the importance of further action from both the company and government authorities.

In response to these developments, AstraZeneca reaffirmed its commitment to patient safety and emphasized that regulatory authorities maintain stringent standards to ensure the safe use of all medicines, including vaccines.

“Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority, and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines,” AstraZeneca said in a statement.

The controversy surrounding the AstraZeneca-Oxford vaccine underscores broader concerns about vaccine safety and the potential for rare but serious side effects. Thrombosis with Thrombocytopenia Syndrome (TTS) has been a subject of investigation and concern, with health authorities closely monitoring and assessing the risk associated with this rare condition.

Despite the legal challenges and controversies, the World Health Organization (WHO) has maintained its endorsement of the AstraZeneca vaccine, stating that it is safe and effective for individuals aged 18 and above. The organization has acknowledged the rare nature of the adverse effects prompting legal action, reiterating that the benefits of vaccination outweigh the risks.

The acknowledgment by AstraZeneca represents a significant development in the ongoing debate over vaccine safety and the accountability of pharmaceutical companies.

As legal proceedings continue and investigations unfold, stakeholders will be closely monitoring the outcomes and implications for public health policy and vaccine development.

In conclusion, AstraZeneca’s admission regarding the rare side effects associated with its Covid-19 vaccine marks a notable shift in the company’s stance, acknowledging the potential risks identified in legal proceedings.